首页> 外文会议>Nihon To?seki Igakkai., Gakujutsu Shu?kai So?kai >Magnesium in Hemodialysis Patients: A New Understanding of the Old Problem
【24h】

Magnesium in Hemodialysis Patients: A New Understanding of the Old Problem

机译:血液透析患者的镁:对旧问题的新了解

获取原文

摘要

Background: Despite the prognostic significance of mineral and bone disorders in patients undergoing hemodialysis, very few studies have focused on magnesium metabolism in this population. Nephrologists have paid much attention to hypermagnesemia, which is sometimes caused by magnesium administration, but the clinical implication of low magnesium has been largely overlooked. Recently, several cohort studies have reported that lower serum magnesium levels are associated with an increased risk of all-cause and cardiovascular mortality among hemodialysis patients. In addition to its beneficial effect on endothelium, magnesium has been shown to inhibit the progression of vascular calcification both in vitro and in vivo. Although the exact underlying mechanism is still uncertain, magnesium can suppress the maturation of calciprotein particles, a candidate culprit for vascular calcification, which is promoted by high phosphate. Thus, magnesium seems to be useful to alleviate the phosphate-induced calcification stress. Consistently, the risk of cardiovascular death associated with hyperphosphate-mia is attenuated among hemodialysis patients with high serum magnesium levels, whereas this risk is exacerbated among those with low serum magnesium levels. In the context of the bone-vascular axis, magnesium may also be involved in the risk of fracture. It should be noted that, although total serum magnesium levels of hemodialysis patients are often above the reference range, the concentration of ionized magnesium, a biologically active form of magnesium, is largely normal or even low. Summary: A growing number of observational studies have uncovered the relationship between lower serum magnesium levels and poorer survival of hemodialysis patients. Magnesium modulates the pathogenesis of mineral and bone disorders and might provide a novel therapeutic approach for vascular calcification. Key Messages: Future intervention studies should clarify whether magnesium supplementation and/or increasing dialysate magnesium concentration improves the prognosis of hemodialysis patients.
机译:背景:尽管矿物质和骨髓疾病的预后意义,但在进行血液透析的患者中,很少有研究专注于该群体中的代谢镁。肾病学家已经关注高级血症,这些血症有时是由镁助药引起的,但低镁的临床意义在很大程度上被忽略了。最近,若干队列研究报道,血清镁水平降低血液透析患者全因血管和心血管死亡率的风险增加。除了对内皮的有益作用外,已显示镁在体外和体内抑制血管钙化的进展。虽然确切的潜在机制仍然不确定,但镁可以抑制钙普雷蛋白颗粒的成熟,血管钙化的候选罪魁祸首,其被高磷酸盐促进。因此,镁似乎有助于缓解磷酸盐诱导的钙化应力。始终如一地,与高磷酸盐 - MIA相关的心血管死亡的风险在血清镁水平的血液透析患者中​​衰减,而这种风险会加剧血清镁水平低的那些。在血管轴的背景下,镁也可以参与裂缝的风险。应当注意,虽然血清血清血清镁水平的血液透析患者通常高于参考范围,但电离镁的浓度,生物活性形式的镁,大部分正常甚至低。发明内容:越来越多的观察性研究已经发现,血清镁水平和血液透析患者的较差的生存之间的关系。镁调节矿物质和骨紊乱的发病机制,可以提供一种新的血管钙化治疗方法。关键消息:未来的干预研究应阐明镁补充剂和/或增加透析液镁浓度是否提高了血液透析患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号